Business
Cellares, which last year became the first company to receive the FDA’s new advanced manufacturing technology designation, expects to support clinical production this year and offer commercial-scale manufacturing services in 2027.
FEATURED STORIES
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Novartis plunked down $650 million in upfront payment for BeiGene’s Tislelizumab, which is already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
While Sutro’s technological platform opens multiple therapeutic doors, the company’s singular focus on homogeneous molecules is a key part of its competitive strategy.
RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
Bluebird bio announced plans to split its genetic disease and oncology businesses. Bluebird bio will stay focused on severe genetic disease and spin out its oncology business into a new company.
Biotech CFOs, optimistic about economic recovery as COVID-19 vaccines role out, are busy digitally transforming their companies for a post-COVID way of working, according to the 2021 BDO Life Sciences CFO Outlook Survey, released January 11.
The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay.
Blacksmith Medicines announced on Friday it had secured a multimillion dollar seed funding deal from Eli Lilly and has entered into a research collaboration with the Indianapolis-based pharmaceutical giant to advance human metalloenzyme targets.
Mana Therapeutics takes aim at solid tumors with allogenic cell therapies and Aulos Bioscience sees a new path for IL-2 monoclonal antibodies.
BioSpace spoke to executives from four companies about their expectations for the conference and the coming year.